Parallel Advisors, LLC Adverum Biotechnologies, Inc. Transaction History

Parallel Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.75 - $1.26 $375 - $630	-500 Reduced 50.0%	500 $0
Q1 2023 May 20, 2024	BUY	$0.62 - $0.85 $620 - $850	1,000 New	1,000 $0
Q3 2021 Nov 02, 2021	SELL	$2.08 - $3.6 $50,148 - $86,796	-24,110 Reduced 96.02%	1,000 $2,000
Q2 2021 Aug 06, 2021	BUY	$3.36 - $10.56 $917 - $2,882	273 Added 1.1%	25,110 $88,000
Q1 2021 Apr 23, 2021	SELL	$9.26 - $14.36 $220,721 - $342,284	-23,836 Reduced 48.97%	24,837 $245,000
Q3 2020 Oct 27, 2020	BUY	$10.3 - $21.64 $9,898 - $20,796	961 Added 2.01%	48,673 $501,000
Q2 2020 Jul 16, 2020	SELL	$8.53 - $25.64 $84,839 - $255,015	-9,946 Reduced 17.25%	47,712 $996,000
Q1 2020 Apr 27, 2020	BUY	$7.98 - $16.32 $460,110 - $940,978	57,658 New	57,658 $563,000

2.53M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $689M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.